Cargando…
Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
The factors determining disease course and survival in fibrotic hypersensitivity pneumonitis (fHP) have not been fully elucidated. The aim of this study was to describe the characteristics of patients with fHP in a real-world cohort and investigate factors associated with worse outcomes. We aimed to...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603296/ https://www.ncbi.nlm.nih.gov/pubmed/34794958 http://dx.doi.org/10.1136/bmjresp-2021-001063 |
_version_ | 1784601741540458496 |
---|---|
author | Barratt, Shaney L Creamer, Andrew W Adamali, Huzaifa I Duckworth, Anna Fallon, Janet Fidan, Silan Nancarrow, Tom Wollerton, Rebecca Steward, Matthew Gooptu, Bibek Gibbons, Michael Woodhead, Felix Alexander Scotton, Chris |
author_facet | Barratt, Shaney L Creamer, Andrew W Adamali, Huzaifa I Duckworth, Anna Fallon, Janet Fidan, Silan Nancarrow, Tom Wollerton, Rebecca Steward, Matthew Gooptu, Bibek Gibbons, Michael Woodhead, Felix Alexander Scotton, Chris |
author_sort | Barratt, Shaney L |
collection | PubMed |
description | The factors determining disease course and survival in fibrotic hypersensitivity pneumonitis (fHP) have not been fully elucidated. The aim of this study was to describe the characteristics of patients with fHP in a real-world cohort and investigate factors associated with worse outcomes. We aimed to explore the use of neutrophil to lymphocyte ratio (NLR) and peripheral blood monocyte levels in predicting mortality. METHODS: A retrospective, multicentre, observational UK cohort study. RESULTS: Patients with fHP were significantly younger than those with idiopathic pulmonary fibrosis (IPF) (median age fHP 73 vs IPF 75 years) and were much more likely to be woman (fHP 61% vs IPF 26%). In almost half of all fHP cases (49%, n=104/211), no causative antigen was identified from either the history or specific antigen testing. Overall, fHP was associated with a better survival than IPF, although median survival of both groups was poor (fHP 62 months vs IPF 52 months). IPF survival in patients with a high NLR was significantly lower than those with a low NLR (44 vs 83 months). A monocyte count ≥0.95 K/uL also predicted significantly poorer outcomes for patients with IPF compared with <0.95 K/uL (33 vs 57 months). In contrast, NLR and monocyte count did not predict survival in the fHP cohort. CONCLUSIONS: Although fHP has a statistically lower mortality than IPF, absolute survival time of both conditions is poor. High baseline NLR and absolute monocyte counts predict worse survival in IPF but not in fHP, highlighting the potential for divergence in their pathogenic mechanisms. |
format | Online Article Text |
id | pubmed-8603296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-86032962021-12-03 Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study Barratt, Shaney L Creamer, Andrew W Adamali, Huzaifa I Duckworth, Anna Fallon, Janet Fidan, Silan Nancarrow, Tom Wollerton, Rebecca Steward, Matthew Gooptu, Bibek Gibbons, Michael Woodhead, Felix Alexander Scotton, Chris BMJ Open Respir Res Interstitial Lung Disease The factors determining disease course and survival in fibrotic hypersensitivity pneumonitis (fHP) have not been fully elucidated. The aim of this study was to describe the characteristics of patients with fHP in a real-world cohort and investigate factors associated with worse outcomes. We aimed to explore the use of neutrophil to lymphocyte ratio (NLR) and peripheral blood monocyte levels in predicting mortality. METHODS: A retrospective, multicentre, observational UK cohort study. RESULTS: Patients with fHP were significantly younger than those with idiopathic pulmonary fibrosis (IPF) (median age fHP 73 vs IPF 75 years) and were much more likely to be woman (fHP 61% vs IPF 26%). In almost half of all fHP cases (49%, n=104/211), no causative antigen was identified from either the history or specific antigen testing. Overall, fHP was associated with a better survival than IPF, although median survival of both groups was poor (fHP 62 months vs IPF 52 months). IPF survival in patients with a high NLR was significantly lower than those with a low NLR (44 vs 83 months). A monocyte count ≥0.95 K/uL also predicted significantly poorer outcomes for patients with IPF compared with <0.95 K/uL (33 vs 57 months). In contrast, NLR and monocyte count did not predict survival in the fHP cohort. CONCLUSIONS: Although fHP has a statistically lower mortality than IPF, absolute survival time of both conditions is poor. High baseline NLR and absolute monocyte counts predict worse survival in IPF but not in fHP, highlighting the potential for divergence in their pathogenic mechanisms. BMJ Publishing Group 2021-11-18 /pmc/articles/PMC8603296/ /pubmed/34794958 http://dx.doi.org/10.1136/bmjresp-2021-001063 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Interstitial Lung Disease Barratt, Shaney L Creamer, Andrew W Adamali, Huzaifa I Duckworth, Anna Fallon, Janet Fidan, Silan Nancarrow, Tom Wollerton, Rebecca Steward, Matthew Gooptu, Bibek Gibbons, Michael Woodhead, Felix Alexander Scotton, Chris Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study |
title | Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study |
title_full | Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study |
title_fullStr | Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study |
title_full_unstemmed | Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study |
title_short | Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study |
title_sort | use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fhp): a multicentre retrospective cohort study |
topic | Interstitial Lung Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603296/ https://www.ncbi.nlm.nih.gov/pubmed/34794958 http://dx.doi.org/10.1136/bmjresp-2021-001063 |
work_keys_str_mv | AT barrattshaneyl useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT creamerandreww useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT adamalihuzaifai useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT duckworthanna useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT fallonjanet useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT fidansilan useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT nancarrowtom useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT wollertonrebecca useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT stewardmatthew useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT gooptubibek useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT gibbonsmichael useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT woodheadfelixalexander useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy AT scottonchris useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy |